TACI: A NOVEL IMMUNE CHECKPOINT IN CHRONIC LYMPHOCYTIC LEUKEMIA
Grant number: 1143687 | Funding period: 2018 - 2020
Chronic Lymphocytic Leukemia (CLL) is a very common blood cancer. CLL cells actively shut down immune defenses in patients. Moreover, current as well as emerging more targeted therapies suppress immunity and over a quarter of patients will die from an infection despite a good response to cancer treatments. Our laboratory has gained new understanding in the mechanism of action of a new treatment for CLL called Ibrutinib. This information allows us to design improved treatment options for CLL.